The Intestinal Microbiome in Triple Negative Breast Cancer Treated With Immunotherapy - Trial NCT06318507
Access comprehensive clinical trial information for NCT06318507 through Pure Global AI's free database. This phase not specified trial is sponsored by Pennington Biomedical Research Center and is currently Recruiting. The study focuses on Breast Neoplasms. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Pennington Biomedical Research Center
Timeline & Enrollment
N/A
Mar 11, 2024
Dec 31, 2025
Primary Outcome
Pathologic Complete Response (pCR)
Summary
This study will determine how the intestinal microbiome differs between patients with obesity
 and early triple-negative breast cancer who achieve a pathologic complete response from
 preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06318507
Non-Device Trial